Zentalis Pharma

$24.75 0.00% ($0.00)

Get ready to invest

About Zentalis Pharma

Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.

Popular Stocks	Price	Change
Nu Holdings NU	$4.03 14.16%	14.16%
AMC AMC	$14.43 17.99%	17.99%
AMD AMD	$102.26 3.55%	3.55%
Nvidia NVDA	$188.11 5.38%	5.38%
Gap, Inc., The GPS	$11.6 4.32%	4.32%
Snap SNAP	$15.58 5.2%	5.2%
Ford F	$13.63 3.89%	3.89%
Apple AAPL	$149.64 4.08%	4.08%
Grab Holdings inc. GRAB	$2.41 3.88%	3.88%
NIO NIO	$16.57 3.37%	3.37%